recombinant human bmp2 protein r d systems (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
95
Structured Review
R&D Systems
recombinant human bmp2 protein r d systems
Recombinant Human Bmp2 Protein R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 218 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+bmp+2/Recombinant+Human+BMP-2+GMP+Protein%2C+CF/pm41932341-856-64-68
Average 95 stars, based on 218 article reviews
Recombinant Human Bmp2 Protein R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 218 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+bmp+2/Recombinant+Human+BMP-2+GMP+Protein%2C+CF/pm41932341-856-64-68
Average 95 stars, based on 218 article reviews
recombinant human bmp2 protein r d systems - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Positive Control:Article Title: Controlled release of bone morphogenetic protein-2 improves motor function after traumatic brain injury in a rat model. Article Snippet: After 480% cell confluence, hBMSCs were extracted and transferred to minimum essential medium-a (a-MEM, Cat# 12561072, Thermo Fisher Scientific) supplemented with 10% certified fetal bovine serum (FBS, Cat# 16000044, Thermo Fisher Scientific), 1% P/S, 10 mM b-glycerophosphate (b-gly, Cat# G9422, Sigma-Aldrich), and 250 mM ascorbic acid-2-phosphate (A2P, Cat# 49752, Sigma-Aldrich). a-MEM supplemented with FBS, P/S, b-gly, and A2P was used as the negative control medium. .. For the positive control medium, the base negative control medium with the addition of 100 ng mL 1 human Article Title: Controlled release of bone morphogenetic protein-2 improves motor function after traumatic brain injury in a rat model Article Snippet: After >80% cell confluence, hBMSCs were extracted and transferred to minimum essential medium-α (α-MEM, Cat# 12561072, Thermo Fisher Scientific) supplemented with 10% certified fetal bovine serum (FBS, Cat# 16000044, Thermo Fisher Scientific), 1% P/S, 10 mM β-glycerophosphate (β-gly, Cat# G9422, Sigma-Aldrich), and 250 μM ascorbic acid-2-phosphate (A2P, Cat# 49752, Sigma-Aldrich). α-MEM supplemented with FBS, P/S, β-gly, and A2P was used as the negative control medium. .. For the positive control medium, the base negative control medium with the addition of 100 ng mL −1 human Negative Control:Article Title: Controlled release of bone morphogenetic protein-2 improves motor function after traumatic brain injury in a rat model. Article Snippet: After 480% cell confluence, hBMSCs were extracted and transferred to minimum essential medium-a (a-MEM, Cat# 12561072, Thermo Fisher Scientific) supplemented with 10% certified fetal bovine serum (FBS, Cat# 16000044, Thermo Fisher Scientific), 1% P/S, 10 mM b-glycerophosphate (b-gly, Cat# G9422, Sigma-Aldrich), and 250 mM ascorbic acid-2-phosphate (A2P, Cat# 49752, Sigma-Aldrich). a-MEM supplemented with FBS, P/S, b-gly, and A2P was used as the negative control medium. .. For the positive control medium, the base negative control medium with the addition of 100 ng mL 1 human Article Title: Controlled release of bone morphogenetic protein-2 improves motor function after traumatic brain injury in a rat model Article Snippet: After >80% cell confluence, hBMSCs were extracted and transferred to minimum essential medium-α (α-MEM, Cat# 12561072, Thermo Fisher Scientific) supplemented with 10% certified fetal bovine serum (FBS, Cat# 16000044, Thermo Fisher Scientific), 1% P/S, 10 mM β-glycerophosphate (β-gly, Cat# G9422, Sigma-Aldrich), and 250 μM ascorbic acid-2-phosphate (A2P, Cat# 49752, Sigma-Aldrich). α-MEM supplemented with FBS, P/S, β-gly, and A2P was used as the negative control medium. .. For the positive control medium, the base negative control medium with the addition of 100 ng mL −1 human Recombinant:Article Title: Controlled release of bone morphogenetic protein-2 improves motor function after traumatic brain injury in a rat model. Article Snippet: After 480% cell confluence, hBMSCs were extracted and transferred to minimum essential medium-a (a-MEM, Cat# 12561072, Thermo Fisher Scientific) supplemented with 10% certified fetal bovine serum (FBS, Cat# 16000044, Thermo Fisher Scientific), 1% P/S, 10 mM b-glycerophosphate (b-gly, Cat# G9422, Sigma-Aldrich), and 250 mM ascorbic acid-2-phosphate (A2P, Cat# 49752, Sigma-Aldrich). a-MEM supplemented with FBS, P/S, b-gly, and A2P was used as the negative control medium. .. For the positive control medium, the base negative control medium with the addition of 100 ng mL 1 human Article Title: The Role of Osteoblasts in Phenotypic Variability of Dominant Osteogenesis Imperfecta: Evidence from Patients and Murine Models. Article Snippet: .. Control and patient osteoblasts were seeded in 12-well plates in technical triplicates and differentiated for 6 weeks in osteoblast differentiation media (αMEM media, 10% FBS, 1% Penicillin–Streptomycin) supplemented with β-glycerol phosphate disodium salt hydrate (2.5 mM, Sigma-Aldrich; St. Louis, MO, USA), (+)-Sodium L-ascorbate (50 μg/mL, Sigma-Aldrich; St. Louis, MO, USA), dexamethasone (10 nM, Sigma-Aldrich; St. Louis, MO, USA), and Article Title: Immobilization of BMP-2 in porous hydrogels to spatially regulate osteogenesis. Article Snippet: Sustained release of bone morphogenetic protein 2 (BMP-2) is used to enhance bone regeneration, but immobilizing BMP-2 in three-dimensional scaffolds could enable spatial regulation of stem cell differentiation and bone formation.. Here, we fabricate porous granular hydrogels presenting BMP-2 on the surface to regulate stem cell growth and differentiation.. Immobilization of BMP-2 and cell-adhesive ligands is achieved by surfacespecific functionalization of microgels, which are jammed to form microporous hydrogels. Article Title: Autocatalytic base editing for RNA-responsive translational control. Article Snippet: .. For differentiation to the bone lineage, we grew the cells in DMEM+ 10% v/v FBS supplemented with 1000ng/mL Article Title: The Role of Osteoblasts in Phenotypic Variability of Dominant Osteogenesis Imperfecta: Evidence from Patients and Murine Models Article Snippet: .. Control and patient osteoblasts were seeded in 12-well plates in technical triplicates and differentiated for 6 weeks in osteoblast differentiation media (αMEM media, 10% FBS, 1% Penicillin–Streptomycin) supplemented with β-glycerol phosphate disodium salt hydrate (2.5 mM, Sigma-Aldrich; St. Louis, MO, USA), (+)-Sodium L-ascorbate (50 μg/mL, Sigma-Aldrich; St. Louis, MO, USA), dexamethasone (10 nM, Sigma-Aldrich; St. Louis, MO, USA), and Article Title: Absence of TRIC-B from type XIV Osteogenesis Imperfecta osteoblasts alters cell adhesion and mitochondrial function - A multi-omics study. Article Snippet: Osteogenesis Imperfecta (OI) is a heritable collagen-related bone dysplasia characterized by bone fractures, growth deficiency and skeletal deformity.. Type XIV OI is a recessive OI form caused by null mutations in TMEM38B, which encodes the ER membrane intracellular cation channel TRIC-B.. Previously, we showed that absence of TMEM38B alters calcium flux in the ER of OI patient osteoblasts and fibroblasts, which further disrupts collagen synthesis and secretion. Article Title: Autocatalytic base editing for RNA-responsive translational control Article Snippet: .. For differentiation to the bone lineage, we grew the cells in DMEM + 10% v/v FBS supplemented with 1000 ng/mL Article Title: Controlled release of bone morphogenetic protein-2 improves motor function after traumatic brain injury in a rat model Article Snippet: After >80% cell confluence, hBMSCs were extracted and transferred to minimum essential medium-α (α-MEM, Cat# 12561072, Thermo Fisher Scientific) supplemented with 10% certified fetal bovine serum (FBS, Cat# 16000044, Thermo Fisher Scientific), 1% P/S, 10 mM β-glycerophosphate (β-gly, Cat# G9422, Sigma-Aldrich), and 250 μM ascorbic acid-2-phosphate (A2P, Cat# 49752, Sigma-Aldrich). α-MEM supplemented with FBS, P/S, β-gly, and A2P was used as the negative control medium. .. For the positive control medium, the base negative control medium with the addition of 100 ng mL −1 human Control:Article Title: The Role of Osteoblasts in Phenotypic Variability of Dominant Osteogenesis Imperfecta: Evidence from Patients and Murine Models. Article Snippet: .. Control and patient osteoblasts were seeded in 12-well plates in technical triplicates and differentiated for 6 weeks in osteoblast differentiation media (αMEM media, 10% FBS, 1% Penicillin–Streptomycin) supplemented with β-glycerol phosphate disodium salt hydrate (2.5 mM, Sigma-Aldrich; St. Louis, MO, USA), (+)-Sodium L-ascorbate (50 μg/mL, Sigma-Aldrich; St. Louis, MO, USA), dexamethasone (10 nM, Sigma-Aldrich; St. Louis, MO, USA), and Article Title: The Role of Osteoblasts in Phenotypic Variability of Dominant Osteogenesis Imperfecta: Evidence from Patients and Murine Models Article Snippet: .. Control and patient osteoblasts were seeded in 12-well plates in technical triplicates and differentiated for 6 weeks in osteoblast differentiation media (αMEM media, 10% FBS, 1% Penicillin–Streptomycin) supplemented with β-glycerol phosphate disodium salt hydrate (2.5 mM, Sigma-Aldrich; St. Louis, MO, USA), (+)-Sodium L-ascorbate (50 μg/mL, Sigma-Aldrich; St. Louis, MO, USA), dexamethasone (10 nM, Sigma-Aldrich; St. Louis, MO, USA), and Article Title: Absence of TRIC-B from type XIV Osteogenesis Imperfecta osteoblasts alters cell adhesion and mitochondrial function - A multi-omics study. Article Snippet: Osteogenesis Imperfecta (OI) is a heritable collagen-related bone dysplasia characterized by bone fractures, growth deficiency and skeletal deformity.. Type XIV OI is a recessive OI form caused by null mutations in TMEM38B, which encodes the ER membrane intracellular cation channel TRIC-B.. Previously, we showed that absence of TMEM38B alters calcium flux in the ER of OI patient osteoblasts and fibroblasts, which further disrupts collagen synthesis and secretion. Modification:Article Title: Immobilization of BMP-2 in porous hydrogels to spatially regulate osteogenesis. Article Snippet: Sustained release of bone morphogenetic protein 2 (BMP-2) is used to enhance bone regeneration, but immobilizing BMP-2 in three-dimensional scaffolds could enable spatial regulation of stem cell differentiation and bone formation.. Here, we fabricate porous granular hydrogels presenting BMP-2 on the surface to regulate stem cell growth and differentiation.. Immobilization of BMP-2 and cell-adhesive ligands is achieved by surfacespecific functionalization of microgels, which are jammed to form microporous hydrogels. Transfection:Article Title: Autocatalytic base editing for RNA-responsive translational control. Article Snippet: .. For differentiation to the bone lineage, we grew the cells in DMEM+ 10% v/v FBS supplemented with 1000ng/mL Article Title: Autocatalytic base editing for RNA-responsive translational control Article Snippet: .. For differentiation to the bone lineage, we grew the cells in DMEM + 10% v/v FBS supplemented with 1000 ng/mL Mineralization Assay:Article Title: Absence of TRIC-B from type XIV Osteogenesis Imperfecta osteoblasts alters cell adhesion and mitochondrial function - A multi-omics study. Article Snippet: Osteogenesis Imperfecta (OI) is a heritable collagen-related bone dysplasia characterized by bone fractures, growth deficiency and skeletal deformity.. Type XIV OI is a recessive OI form caused by null mutations in TMEM38B, which encodes the ER membrane intracellular cation channel TRIC-B.. Previously, we showed that absence of TMEM38B alters calcium flux in the ER of OI patient osteoblasts and fibroblasts, which further disrupts collagen synthesis and secretion. Staining:Article Title: Absence of TRIC-B from type XIV Osteogenesis Imperfecta osteoblasts alters cell adhesion and mitochondrial function - A multi-omics study. Article Snippet: Osteogenesis Imperfecta (OI) is a heritable collagen-related bone dysplasia characterized by bone fractures, growth deficiency and skeletal deformity.. Type XIV OI is a recessive OI form caused by null mutations in TMEM38B, which encodes the ER membrane intracellular cation channel TRIC-B.. Previously, we showed that absence of TMEM38B alters calcium flux in the ER of OI patient osteoblasts and fibroblasts, which further disrupts collagen synthesis and secretion. |
![Comparative effects of BMP9 and <t>BMP2</t> on osteogenic differentiation and osteoclastogenesis in vitro. (A) Real‐time PCR analysis of key osteogenic genes (Col1, Runx2, ALP, and OCN) in MC3T3‐E1 cells treated with 8 nM of BMP2 or BMP9 for 3, 5, and 7 days. All gene‐expression levels were normalized to GAPDH. (B) Western blot analysis of osteogenic marker proteins in cell lysates harvested after 7 days of treatment with BMP2 or BMP9. GAPDH was used as the loading control. Densitometric quantification of band intensities (integrated density) normalized to GAPDH is shown below the blots and presented as relative protein expression. (C) Western blot showing dose‐dependent p‐Smad1/5/9 in MC3T3‐E1 cells exposed to varying concentrations of BMP2 or BMP9. Phosphorylation was quantified by densitometry and expressed as fold change vs. control after normalization using [(p‐Smad1/5/9)/(total Smad1/5/9)] and further normalized to GAPDH, as shown in the graph below the blots. Asterisks indicate statistical significance for pairwise comparisons between BMP2 and BMP9 at the same concentration (****, p < 0.0001), unless otherwise indicated. (D) ALP activity and representative images of ALP staining in MC3T3‐E1 cultures after 7 days of induction with BMP2 or BMP9. (E) Alizarin Red S staining illustrating mineralized nodule formation after extended culture with BMP2 or BMP9. (F) Representative TRAP‐stained images of RAW 264.7‐derived osteoclasts following treatment with RANKL (3 nM), BMP2 (8 nM), or BMP9 (8 nM) for 5 days. TRAP‐positive multinucleated osteoclasts are indicated by arrows. Scale bar, 20 μm. (G) Quantification of TRAP‐positive multinucleated cells per well. Data are presented as the mean ± SD ( n = 3 independent experiments), and p ‐values were calculated using one‐way analysis of variance (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). BMP, bone morphogenetic protein; PCR, polymerase chain reaction; ALP, alkaline phosphatase; Col1, collagen type I; Runx2, runt‐related transcription factor 2; OCN, osteocalcin; GAPDH, glyceraldehyde‐3‐phosphate dehydrogenase.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_4554/pmc12974554/pmc12974554__CID-28-0-g002.jpg)
